APO Research
Talk to an analyst

APO RESEARCH · REPORT

Epoprostenol

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Epoprostenol Market Outlook and Growth Opportunities 2026

21 December 2025197 pages

Choose your research edition.

Industry ResearchEpoprostenol Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Epoprostenol Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Epoprostenol Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Epoprostenol Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Epoprostenol Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Epoprostenol market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Epoprostenol is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Epoprostenol is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Epoprostenol is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Epoprostenol market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Epoprostenol market include Teva Parenteral, Merck, Glaxosmithkline Inc, Bayer AG, SteadyMed, Sandoz Canada Incorporated, Reata Pharmaceuticals, Arena Pharmaceuticals and Actelion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Epoprostenol market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Epoprostenol and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Epoprostenol sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Epoprostenol market size, projected growth trends, production technologies, key applications, and end-use industries.

Epoprostenol Segment by Company

Teva Parenteral

Merck

Glaxosmithkline Inc

Bayer AG

SteadyMed

Sandoz Canada Incorporated

Reata Pharmaceuticals

Arena Pharmaceuticals

Actelion

Epoprostenol Segment by Type

Oral Epoprostenol

Injection Epoprostenol

Epoprostenol Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Epoprostenol Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Epoprostenol status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Epoprostenol market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Epoprostenol significant trends, drivers, influence factors in global and regions.

6. To analyze Epoprostenol competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epoprostenol market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Epoprostenol and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epoprostenol.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Epoprostenol market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Epoprostenol industry.

Chapter 3: Detailed analysis of Epoprostenol manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Epoprostenol in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Epoprostenol in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Epoprostenol Industry Trends Table 2. Epoprostenol Industry Drivers Table 3. Epoprostenol Industry Opportunities and Challenges Table 4. Epoprostenol Industry Restraints Table 5. Global Epoprostenol Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Epoprostenol Revenue Share by Company (2021-2026) Table 7. Global Epoprostenol Sales Volume by Company (tons) & (2021-2026) Table 8. Global Epoprostenol Sales Volume Share by Company (2021-2026) Table 9. Global Epoprostenol Average Price (US$/ton) of Company (2021-2026) Table 10. Global Epoprostenol Company Ranking, (2024-2026) & (USD Million) Table 11. Global Epoprostenol Key Company Manufacturing Base & Headquarters Table 12. Global Epoprostenol Company, Product Type & Application Table 13. Global Epoprostenol Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Epoprostenol by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Epoprostenol Table 18. Significant Companies of Injection Epoprostenol Table 19. Global Epoprostenol Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 20. Global Epoprostenol Sales Volume by Type (2021-2026) & (tons) Table 21. Global Epoprostenol Sales Volume by Type (2027-2032) & (tons) Table 22. Global Epoprostenol Sales Volume Share by Type (2021-2026) Table 23. Global Epoprostenol Sales Volume Share by Type (2027-2032) Table 24. Global Epoprostenol Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Epoprostenol Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Epoprostenol Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Epoprostenol Sales Value Share by Type (2021-2026) Table 28. Global Epoprostenol Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Retail Pharmacy Table 30. Significant Companies of Online Pharmacy Table 31. Significant Companies of Hospital Pharmacy Table 32. Global Epoprostenol Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 33. Global Epoprostenol Sales Volume by Application (2021-2026) & (tons) Table 34. Global Epoprostenol Sales Volume by Application (2027-2032) & (tons) Table 35. Global Epoprostenol Sales Volume Share by Application (2021-2026) Table 36. Global Epoprostenol Sales Volume Share by Application (2027-2032) Table 37. Global Epoprostenol Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Epoprostenol Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Epoprostenol Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Epoprostenol Sales Value Share by Application (2021-2026) Table 41. Global Epoprostenol Sales Value Share by Application (2027-2032) Table 42. Global Epoprostenol Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 43. Global Epoprostenol Sales by Region (2021-2026) & (tons) Table 44. Global Epoprostenol Sales Market Share by Region (2021-2026) Table 45. Global Epoprostenol Sales by Region (2027-2032) & (tons) Table 46. Global Epoprostenol Sales Market Share by Region (2027-2032) Table 47. Global Epoprostenol Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Epoprostenol Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Epoprostenol Sales Value Share by Region (2021-2026) Table 50. Global Epoprostenol Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Epoprostenol Sales Value Share by Region (2027-2032) Table 52. Global Epoprostenol Market Average Price (US$/ton) by Region (2021-2026) Table 53. Global Epoprostenol Market Average Price (US$/ton) by Region (2027-2032) Table 54. Global Epoprostenol Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 55. Global Epoprostenol Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Epoprostenol Sales by Country (2021-2026) & (tons) Table 57. Global Epoprostenol Sales Market Share by Country (2021-2026) Table 58. Global Epoprostenol Sales by Country (2027-2032) & (tons) Table 59. Global Epoprostenol Sales Market Share by Country (2027-2032) Table 60. Global Epoprostenol Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Epoprostenol Sales Value Market Share by Country (2021-2026) Table 62. Global Epoprostenol Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Epoprostenol Sales Value Market Share by Country (2027-2032) Table 64. Teva Parenteral Company Information Table 65. Teva Parenteral Business Overview Table 66. Teva Parenteral Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Teva Parenteral Epoprostenol Product Portfolio Table 68. Teva Parenteral Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Merck Epoprostenol Product Portfolio Table 73. Merck Recent Development Table 74. Glaxosmithkline Inc Company Information Table 75. Glaxosmithkline Inc Business Overview Table 76. Glaxosmithkline Inc Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Glaxosmithkline Inc Epoprostenol Product Portfolio Table 78. Glaxosmithkline Inc Recent Development Table 79. Bayer AG Company Information Table 80. Bayer AG Business Overview Table 81. Bayer AG Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Bayer AG Epoprostenol Product Portfolio Table 83. Bayer AG Recent Development Table 84. SteadyMed Company Information Table 85. SteadyMed Business Overview Table 86. SteadyMed Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. SteadyMed Epoprostenol Product Portfolio Table 88. SteadyMed Recent Development Table 89. Sandoz Canada Incorporated Company Information Table 90. Sandoz Canada Incorporated Business Overview Table 91. Sandoz Canada Incorporated Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Sandoz Canada Incorporated Epoprostenol Product Portfolio Table 93. Sandoz Canada Incorporated Recent Development Table 94. Reata Pharmaceuticals Company Information Table 95. Reata Pharmaceuticals Business Overview Table 96. Reata Pharmaceuticals Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Reata Pharmaceuticals Epoprostenol Product Portfolio Table 98. Reata Pharmaceuticals Recent Development Table 99. Arena Pharmaceuticals Company Information Table 100. Arena Pharmaceuticals Business Overview Table 101. Arena Pharmaceuticals Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Arena Pharmaceuticals Epoprostenol Product Portfolio Table 103. Arena Pharmaceuticals Recent Development Table 104. Actelion Company Information Table 105. Actelion Business Overview Table 106. Actelion Epoprostenol Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. Actelion Epoprostenol Product Portfolio Table 108. Actelion Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Epoprostenol Distributors List Table 112. Epoprostenol Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Epoprostenol Product Image Figure 2. Global Epoprostenol Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Epoprostenol Sales Value (2021-2032) & (US$ Million) Figure 4. Global Epoprostenol Sales (2021-2032) & (tons) Figure 5. Global Epoprostenol Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Epoprostenol Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Epoprostenol Image Figure 10. Injection Epoprostenol Image Figure 11. Global Epoprostenol Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 12. Global Epoprostenol Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Epoprostenol Sales Volume Share by Type (2021-2032) Figure 14. Global Epoprostenol Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Epoprostenol Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Epoprostenol Sales Value Share by Type (2021-2032) Figure 17. Retail Pharmacy Image Figure 18. Online Pharmacy Image Figure 19. Hospital Pharmacy Image Figure 20. Global Epoprostenol Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 21. Global Epoprostenol Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Epoprostenol Sales Volume Share by Application (2021-2032) Figure 23. Global Epoprostenol Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Epoprostenol Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Epoprostenol Sales Value Share by Application (2021-2032) Figure 26. Global Epoprostenol Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 27. Global Epoprostenol Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Epoprostenol Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Epoprostenol Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Epoprostenol Sales Value (2021-2032) & (US$ Million) Figure 31. North America Epoprostenol Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Epoprostenol Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Epoprostenol Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Epoprostenol Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Epoprostenol Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Epoprostenol Sales Value (2021-2032) & (US$ Million) Figure 37. South America Epoprostenol Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Epoprostenol Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Epoprostenol Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Epoprostenol Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Epoprostenol Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Epoprostenol Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Epoprostenol Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Epoprostenol Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Epoprostenol
  • Injection Epoprostenol
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Teva Parenteral
  • Merck
  • Glaxosmithkline Inc
  • Bayer AG
  • SteadyMed
  • Sandoz Canada Incorporated
  • Reata Pharmaceuticals
  • Arena Pharmaceuticals
  • Actelion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Epoprostenol Sales Value (2021-2032)
  4. 1.2.2 Global Epoprostenol Sales Volume (2021-2032)
  5. 1.2.3 Global Epoprostenol Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Epoprostenol Market Dynamics
  1. 2.1 Epoprostenol Industry Trends
  2. 2.2 Epoprostenol Industry Drivers
  3. 2.3 Epoprostenol Industry Opportunities and Challenges
  4. 2.4 Epoprostenol Industry Restraints
3 Epoprostenol Market by Company
  1. 3.1 Global Epoprostenol Company Revenue Ranking in 2025
  2. 3.2 Global Epoprostenol Revenue by Company (2021-2026)
  3. 3.3 Global Epoprostenol Sales Volume by Company (2021-2026)
  4. 3.4 Global Epoprostenol Average Price by Company (2021-2026)
  5. 3.5 Global Epoprostenol Company Ranking (2024-2026)
  6. 3.6 Global Epoprostenol Company Manufacturing Base and Headquarters
  7. 3.7 Global Epoprostenol Company Product Type and Application
  8. 3.8 Global Epoprostenol Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Epoprostenol Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Epoprostenol Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Epoprostenol Market by Type
  1. 4.1 Epoprostenol Type Introduction
  2. 4.1.1 Oral Epoprostenol
  3. 4.1.2 Injection Epoprostenol
  4. 4.2 Global Epoprostenol Sales Volume by Type
  5. 4.2.1 Global Epoprostenol Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Epoprostenol Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Epoprostenol Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Epoprostenol Sales Value by Type
  9. 4.3.1 Global Epoprostenol Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Epoprostenol Sales Value by Type (2021-2032)
  11. 4.3.3 Global Epoprostenol Sales Value Share by Type (2021-2032)
5 Epoprostenol Market by Application
  1. 5.1 Epoprostenol Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.2 Global Epoprostenol Sales Volume by Application
  6. 5.2.1 Global Epoprostenol Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Epoprostenol Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Epoprostenol Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Epoprostenol Sales Value by Application
  10. 5.3.1 Global Epoprostenol Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Epoprostenol Sales Value by Application (2021-2032)
  12. 5.3.3 Global Epoprostenol Sales Value Share by Application (2021-2032)
6 Epoprostenol Regional Sales and Value Analysis
  1. 6.1 Global Epoprostenol Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Epoprostenol Sales by Region (2021-2032)
  3. 6.2.1 Global Epoprostenol Sales by Region: 2021-2026
  4. 6.2.2 Global Epoprostenol Sales by Region (2027-2032)
  5. 6.3 Global Epoprostenol Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Epoprostenol Sales Value by Region (2021-2032)
  7. 6.4.1 Global Epoprostenol Sales Value by Region: 2021-2026
  8. 6.4.2 Global Epoprostenol Sales Value by Region (2027-2032)
  9. 6.5 Global Epoprostenol Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Epoprostenol Sales Value (2021-2032)
  12. 6.6.2 North America Epoprostenol Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Epoprostenol Sales Value (2021-2032)
  15. 6.7.2 Europe Epoprostenol Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Epoprostenol Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Epoprostenol Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Epoprostenol Sales Value (2021-2032)
  21. 6.9.2 South America Epoprostenol Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Epoprostenol Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Epoprostenol Sales Value Share by Country, 2025 VS 2032
7 Epoprostenol Country-level Sales and Value Analysis
  1. 7.1 Global Epoprostenol Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Epoprostenol Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Epoprostenol Sales by Country (2021-2032)
  4. 7.3.1 Global Epoprostenol Sales by Country (2021-2026)
  5. 7.3.2 Global Epoprostenol Sales by Country (2027-2032)
  6. 7.4 Global Epoprostenol Sales Value by Country (2021-2032)
  7. 7.4.1 Global Epoprostenol Sales Value by Country (2021-2026)
  8. 7.4.2 Global Epoprostenol Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Epoprostenol Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Epoprostenol Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Epoprostenol Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Epoprostenol Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Epoprostenol Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Epoprostenol Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Epoprostenol Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Epoprostenol Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Epoprostenol Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Epoprostenol Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Epoprostenol Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Epoprostenol Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Epoprostenol Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Epoprostenol Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Epoprostenol Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Epoprostenol Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Epoprostenol Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Epoprostenol Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Epoprostenol Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Epoprostenol Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Epoprostenol Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Epoprostenol Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Epoprostenol Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Epoprostenol Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Epoprostenol Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Epoprostenol Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Epoprostenol Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Epoprostenol Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Epoprostenol Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Epoprostenol Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Epoprostenol Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Epoprostenol Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Epoprostenol Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Epoprostenol Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Epoprostenol Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Epoprostenol Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Epoprostenol Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Epoprostenol Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Epoprostenol Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Epoprostenol Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Epoprostenol Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Epoprostenol Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Epoprostenol Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Epoprostenol Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Epoprostenol Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Epoprostenol Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Epoprostenol Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Epoprostenol Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Epoprostenol Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Epoprostenol Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Epoprostenol Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Epoprostenol Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Epoprostenol Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Epoprostenol Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Epoprostenol Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Epoprostenol Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Epoprostenol Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Epoprostenol Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Epoprostenol Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Epoprostenol Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Epoprostenol Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Epoprostenol Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Epoprostenol Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Epoprostenol Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Epoprostenol Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Epoprostenol Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Epoprostenol Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Epoprostenol Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Epoprostenol Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Epoprostenol Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Epoprostenol Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Epoprostenol Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Epoprostenol Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Epoprostenol Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Epoprostenol Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Epoprostenol Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Epoprostenol Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Epoprostenol Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Epoprostenol Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Epoprostenol Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Epoprostenol Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Epoprostenol Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Epoprostenol Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Epoprostenol Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Parenteral
  2. 8.1.1 Teva Parenteral Company Information
  3. 8.1.2 Teva Parenteral Business Overview
  4. 8.1.3 Teva Parenteral Epoprostenol Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Parenteral Epoprostenol Product Portfolio
  6. 8.1.5 Teva Parenteral Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Epoprostenol Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Epoprostenol Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Glaxosmithkline Inc
  14. 8.3.1 Glaxosmithkline Inc Company Information
  15. 8.3.2 Glaxosmithkline Inc Business Overview
  16. 8.3.3 Glaxosmithkline Inc Epoprostenol Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Glaxosmithkline Inc Epoprostenol Product Portfolio
  18. 8.3.5 Glaxosmithkline Inc Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Epoprostenol Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Epoprostenol Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 SteadyMed
  26. 8.5.1 SteadyMed Company Information
  27. 8.5.2 SteadyMed Business Overview
  28. 8.5.3 SteadyMed Epoprostenol Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 SteadyMed Epoprostenol Product Portfolio
  30. 8.5.5 SteadyMed Recent Developments
  31. 8.6 Sandoz Canada Incorporated
  32. 8.6.1 Sandoz Canada Incorporated Company Information
  33. 8.6.2 Sandoz Canada Incorporated Business Overview
  34. 8.6.3 Sandoz Canada Incorporated Epoprostenol Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz Canada Incorporated Epoprostenol Product Portfolio
  36. 8.6.5 Sandoz Canada Incorporated Recent Developments
  37. 8.7 Reata Pharmaceuticals
  38. 8.7.1 Reata Pharmaceuticals Company Information
  39. 8.7.2 Reata Pharmaceuticals Business Overview
  40. 8.7.3 Reata Pharmaceuticals Epoprostenol Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Reata Pharmaceuticals Epoprostenol Product Portfolio
  42. 8.7.5 Reata Pharmaceuticals Recent Developments
  43. 8.8 Arena Pharmaceuticals
  44. 8.8.1 Arena Pharmaceuticals Company Information
  45. 8.8.2 Arena Pharmaceuticals Business Overview
  46. 8.8.3 Arena Pharmaceuticals Epoprostenol Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Arena Pharmaceuticals Epoprostenol Product Portfolio
  48. 8.8.5 Arena Pharmaceuticals Recent Developments
  49. 8.9 Actelion
  50. 8.9.1 Actelion Company Information
  51. 8.9.2 Actelion Business Overview
  52. 8.9.3 Actelion Epoprostenol Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Actelion Epoprostenol Product Portfolio
  54. 8.9.5 Actelion Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Epoprostenol Value Chain Analysis
  2. 9.1.1 Epoprostenol Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Epoprostenol Sales Mode & Process
  6. 9.2 Epoprostenol Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Epoprostenol Distributors
  9. 9.2.3 Epoprostenol Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst